Hcw Biologics Inc. (HCWB) intrinsic value & 10-year financials
Hcw Biologics Inc. (HCWB) has a Graham intrinsic value of $984.05 per share. At $1.24 on Oct 17, 2026, the stock trades 100% below that value. Over the last 7 fiscal years revenue shrank 57.9% a year to $54.2K, with an average return on invested capital of -112.1%.
- Graham intrinsic value
- $984.05
- Share price (Oct 17, 2026)
- $1.24
- Price vs Graham value
- 100% below
- Market cap
- $2.6M
- Revenue (FY2025)
- $54.2K
- Revenue growth (7-yr CAGR)
- -57.9%
- ROIC (10-yr avg)
- -112.1%
- Free cash flow (FY2025)
- -$13.4M
HCWB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $54.2K | -$8.0M | -$10.63 | -$13.4M | -24270.7% | -266.7% |
| FY2024 | $2.6M | -$30.0M | -$0.77 | -$14.5M | -1148.5% | -318.0% |
| FY2023 | $2.8M | -$25.0M | -$0.70 | -$28.7M | -905.0% | -67.6% |
| FY2022 | $6.7M | -$14.9M | -$0.42 | -$20.7M | -224.3% | -30.4% |
| FY2021 | $0 | -$12.9M | -$0.34 | -$11.0M | — | -33.9% |
| FY2020 | $4.1M | -$5.8M | — | -$10.6M | -142.1% | 44.1% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
HCW Biologics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
HCW Biologics Inc. has historically struggled to out-earn its cost of capital, averaging just -15.6% ROIC.
HCW Biologics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, HCW Biologics Inc. is modeled at -57.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $984.05 per share.